Arthritis Advisory Committee March 4, 2003 Presented at the Arthritis Advisory Committee meeting on March 4, 2003 by Jeffrey N. Siegel, M.D.

Slides:

Advertisements

Similar presentations

ANTI-CYTOKINE THERAPY. TNF IN RA INCREASED IN SYNOVIAL FLUID PRODUCED BY SYNOVIOCYTES/MACROPHAGE STIMULATES IL-1, IL-6 PRODUCTION STIMULATES MMP PRODUCTION.

Advertisements

Efficacy of Methotrexate and/or Etanercept for treatment of RA Rheumatoid Arthritis:

Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.

Capturing and Reporting Adverse Events in Clinical Research

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

Anti-TNF-  Strategies in CHF: Data from Randomized, Controlled Clinical Trials Arthritis Advisory Committee March 4, 2003 Ellis F. Unger, M.D. Office.

Interpreting Adverse Signals in Diabetes Drug Development Programs Featured Article: Clifford J. Bailey, Ph.D. Diabetes Care Volume 36: 1-9 July, 2013.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center.

BADBIR BAD Biologic Interventions Register Dr Kathy McElhone 27 th June 2012.

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis.

BAD Biologic Interventions Register (BADBIR ) An update November 2010.

 Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.

Safety & Efficacy Update on Approved TNF-Blocking Agents Jeffrey N. Siegel, M.D. OTRR, CBER / FDA Arthritis Advisory Committee March 4, 2003 Jeffrey N.

Abatacept (ORENCIA) for Rheumatoid Arthritis Biological License Application Arthritis Advisory Committee September 6, 2005.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

British Association of Dermatologists’ Biologic Intervention Register (BADBIR) Update November 2007.

1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.

Development and Approval of Drugs and Devices EPI260 Lecture 9 May 23, 2012 Richard Chin, M.D.

Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.

Overview of Issues for Psychopharmacological Drugs Advisory Committee June 16, 2003 WBC Monitoring for Clozapine Judith A. Racoosin, MD, MPH Safety Team.

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

Arthritis Advisory Committee August 16, 2001

CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.

CTD, Safety Tanja Braakman Genzyme Europe BV Pharmacovigilance Department.

Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.

1 Can One Evaluate An Outcomes Claim Based On An Active Controlled Study? Pfizer Response Cardiovascular and Renal Drugs Advisory Committee Rockville,

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

BAD Biologic Interventions Register (BADBIR ) An update November 2009.

Risk Management in premarketing phase Anshu Vashishtha MD PhD (in individual capacity employer : Watson Pharmaceuticals)

1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.

VIOXX ™ Gastrointestinal Outcome Research (VIGOR) Arthritis Advisory Committee Meeting February 8, 2001 Lourdes Villalba, M.D. DAAODP, CDER, FDA.

1 Presented by Eugene Laska, Ph.D. at the Arthritis Advisory Committee meeting 07/30/02.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.

DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.

Celecoxib for JRA: Assessing Risks & Benefits Jeffrey Siegel, M.D. FDA/CDER/ODE2/DAARP Arthritis Advisory Committee November 29, 2006.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting April 12, 2007 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

1 Assessing Cancer Risk & Assuring Safe Use of Topical Immunosuppressants: Recent History Susan K. Cummins, MD, MPH Medical Team Leader OCTAP and OPT.

Concerns About Adverse Event Reporting in Randomized Clinical Trials Yusuf Yazıcı, MD NYU Hospital for Joint Diseases

1 TNF Blocker Safety: Lymphoma and Liver Failure Tim Coté MD MPH, Chief, Therapeutics & Blood Safety Branch, DE/OBE/CBER/FDA March 4, 2003.

Arthritis Advisory Committee March 4, 2003 Update on the Safety of TNF Blockers Li-ching Liang, M.D. FDA / CBER/ OTRR Arthritis Advisory Committee March.

Sertraline Use in Pediatric Population: A Risk Benefit Discussion Steven J. Romano, MD September 13, 2004 Steven J. Romano, MD September 13, 2004 Joint.

Peripheral and Central Nervous System Drugs Advisory Committee Meeting - March 14, Issues Related to the Development of Drugs for the Treatment.

Advisory Committee Presentation on Vioxx (Rofecoxib) Discussion on the meta analyses for cardiovascular risk assessment Qian Li, Sc. D.

FDA1 Overview of Postmarketing Safety Surveillance in FDA (For Drugs and Biologics) Min Chen, M.S., R.Ph. Min Chen, M.S., R.Ph. Associate Director Division.

1 Cardiovascular and Renal Drugs Advisory Committee Questions June 24, 2008 Ira Krefting, MD.

Minimum requirements for Pharmacovigilance in countries.

European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.

1 FDA Guidance for Industry Development and Use of Risk Minimization Action Plans Anne Trontell, M.D., M.P.H. Deputy Director CDER Office of Drug Safety.

CDRH Advisory Committee Meeting: Orthopedic and Rehabilitation Devices Panel November 20, 2002 INDEPENDENCE™ iBOT™ 3000 Mobility System Independence Technology.

Comments on FDA Concept Paper Sidney N. Kahn, MD, PhD President Pharmacovigilance & Risk Management, Inc. Risk Assessment of Observational.

Circulatory System Devices Panel Questions for Discussion EMBOL·X Aortic Filter October 23, 2002.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.

Research Activities at The Boston Collaborative Drug Surveillance Program; Boston University School of Public Health Susan Jick Professor of Epidemiology.

Volume 18, Issue 2, Pages (March 2015)

EudraVigilance.

Martha Carvour, MD, PhD March 2, 2017

Psoriasis What’s New Dr. Vincent P Beltrani

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis Alan Menter,

Minding the Gap Rheumatoid Arthritis Advances From London 2016

What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data

Precision Management of RA and Comorbidities

remember to round it to whole numbers

When Is Biologic Therapy Appropriate for HS?

Safety, efficacy, and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis Alexander Egeberg, MD PhD; Mathias Bo Ottosen,

PPI prophylaxis for GI bleeding in ICU

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Presentation transcript:

Arthritis Advisory Committee March 4, 2003 Presented at the Arthritis Advisory Committee meeting on March 4, 2003 by Jeffrey N. Siegel, M.D.

Arthritis Advisory Committee March 4, Adalimumab: Lymphomas Controlled portions of controlled trials: –Adalimumab: 2 cases among 1380 patients, 0.6 yrs mean exposure –Placebo: 0 cases among 690 patients, 0.5 yrs mean exposure Overall database: 10 cases among 2400 patients, 2.4 yrs median exposure, SIR 5.42 (2.6, 10.0) Controlled portions of controlled trials: –Adalimumab: 2 cases among 1380 patients, 0.6 yrs mean exposure –Placebo: 0 cases among 690 patients, 0.5 yrs mean exposure Overall database: 10 cases among 2400 patients, 2.4 yrs median exposure, SIR 5.42 (2.6, 10.0)

Arthritis Advisory Committee March 4, Etanercept: Lymphomas Controlled portions of controlled trials: –Etanercept: 1 case among 2502 patients, 0.5 yrs mean exposure –Placebo: 0 cases among 921 patients, 0.5 yrs mean exposure Overall database: 6 cases among 3389 patients, 2.2 yrs mean exposure, SIR 2.31 (0.85, 5.03) Controlled portions of controlled trials: –Etanercept: 1 case among 2502 patients, 0.5 yrs mean exposure –Placebo: 0 cases among 921 patients, 0.5 yrs mean exposure Overall database: 6 cases among 3389 patients, 2.2 yrs mean exposure, SIR 2.31 (0.85, 5.03)

Arthritis Advisory Committee March 4, Infliximab: Lymphomas Controlled portions of controlled trials: –Infliximab: 3 cases among 2421 patients, 1.0 yrs mean exposure –Placebo: 0 cases among 489 patients, 0.9 yrs mean exposure Overall database: 6 cases among 2421 patients, 1.7 yrs mean exposure, SIR 6.98 (2.56, 15.19) Controlled portions of controlled trials: –Infliximab: 3 cases among 2421 patients, 1.0 yrs mean exposure –Placebo: 0 cases among 489 patients, 0.9 yrs mean exposure Overall database: 6 cases among 2421 patients, 1.7 yrs mean exposure, SIR 6.98 (2.56, 15.19)

Arthritis Advisory Committee March 4, Concluding Remarks: Lymphomas Newer data show occurrence of lymphomas with each of the approved agents: –In controlled trials, 1-3 cases with study drugs vs. 0 with placebo –Controlled plus non-controlled extension trials showed higher rate than in general US population –Additional cases in post-marketing experience Higher reported rates in RA patients complicates analysis Newer data show occurrence of lymphomas with each of the approved agents: –In controlled trials, 1-3 cases with study drugs vs. 0 with placebo –Controlled plus non-controlled extension trials showed higher rate than in general US population –Additional cases in post-marketing experience Higher reported rates in RA patients complicates analysis

Arthritis Advisory Committee March 4, CHFCHF Deleterious effects of infliximab in CHF patients Concerning trends in CHF patients receiving etanercept Adalimumab – not known Deleterious effects of infliximab in CHF patients Concerning trends in CHF patients receiving etanercept Adalimumab – not known

Arthritis Advisory Committee March 4, ConclusionsConclusions Approved TNF blockers associated with high ACR response rates in RA, beneficial effects in progression of structural damage –For infliximab, demonstrated improvement in HAQ in long-term study A number of serious, but uncommon, adverse reactions also associated with their use For some adverse events, risks can be reduced with appropriate screening Approved TNF blockers associated with high ACR response rates in RA, beneficial effects in progression of structural damage –For infliximab, demonstrated improvement in HAQ in long-term study A number of serious, but uncommon, adverse reactions also associated with their use For some adverse events, risks can be reduced with appropriate screening

Arthritis Advisory Committee March 4, Risk Management Important to: –Maximize benefit –Minimize risk For identified risks of TNF blockers: –Collect data to accurately assess risk –Minimize risks where appropriate by patient selection and screening –Risk communication Important to: –Maximize benefit –Minimize risk For identified risks of TNF blockers: –Collect data to accurately assess risk –Minimize risks where appropriate by patient selection and screening –Risk communication

Arthritis Advisory Committee March 4, Agency Welcomes Discussion of: For lymphoma –Confounding factors in assessing causal relationships –Likelihood of causal relationship between lymphomas & TNF blockers –How to collect data that would help assess causal associations –Appropriate language for labels to communicate available information For CHF –Approaches to risk management For lymphoma –Confounding factors in assessing causal relationships –Likelihood of causal relationship between lymphomas & TNF blockers –How to collect data that would help assess causal associations –Appropriate language for labels to communicate available information For CHF –Approaches to risk management